Table 1.

Patient characteristics and clinical response

PatientAge (y)SexPrimaryPalliative chemotherapySites of disease at screeningTrial: cyclesBest CT responseSerum tumor antigen changeOS (mo)
141MEECFL, N, liver, lung1PDIncrease2.73
363MGEJCFL, N1PDDecrease10.17
437FGMCXDuodenal mass, ascites, peritoneal, pelvic2SDStable12.20
555MECFL, N, liver, lung, bone1PDIncrease1.70
639MGECF, ECXL, N1PDIncrease3.63
763MGEJCFL, N, lung2PDIncrease7.27
843FGECX, D/IL, omental, serosal, ascites1PD12.03
957MGC/TS1L, N, pleural effusion, ascites1PD4.27
1075FGMCXL, N, liver1PDIncrease4.60
1149MEECFL, adrenal, chest wall, muscle1PDIncrease2.20
1267MEECXL, N, liver, lung, adrenal, pleural, bone11PRDecrease32.70+
1375MGEJMCXL, N, lung, pleural effusion1*Increase3.73
1461FGECF, MCFN, splenic1PDDecrease17.93
1568MGEJECXL, N, liver, lung2PDIncrease17.10
1641MGEJCFL, N1PDIncrease4.83
1762MEMCXL (pericardium and diaphragm)2SDIncrease12.83
1853MGEJECFL, liver, chest wall1PDIncrease4.70

Abbreviations: D/I, Docetaxel/Irinotecan; OS, overall survival; ES, esophageal; G, gastric; GEJ, gastroesophageal junction; E, epirubicin; C, cisplatin; F, 5-fluorouracil; M, mitomycin; X, capecitabine; TS1, an oral 5-fluorouracil derivative; L, local; N, lymph node; PD, progressive disease; SD, stable disease; PR, partial response; +, patient still alive.